慢性完全闭塞病变PCI与药物治疗的生活质量:EUROCTO与DECISION-CTO荟萃分析
该研究基于EUROCTO和DECISION-CTO两项随机试验的事后汇总分析,纳入518例仅有一处慢性完全闭塞且无其他显著冠脉病变的患者,比较经皮冠状动脉介入治疗(PCI)与优化药物治疗(OMT)对生活质量和心绞痛的影响。结果显示PCI在改善心绞痛频率、生活质量和SAQ汇总评分方面优于OMT,临床终点无显著差异。
要点
- PCI较OMT显著改善12个月心绞痛频率、生活质量和SAQ汇总评分。
- 基线SAQ评分低和接受PCI是生活质量显著改善的主要决定因素。
- 两组心脏死亡或非致死性心肌梗死、卒中或出血住院率相似。
核心结论
- 在仅有一处慢性完全闭塞且无其他显著冠脉病变的患者中,PCI对生活质量的改善优于OMT,且临床终点无额外危害信号。
研究设计与样本
- EUROCTO和DECISION-CTO两项随机试验的事后汇总分析,共纳入518例仅有一处慢性完全闭塞且无其他显著冠脉病变的患者。
主要发现
- PCI成功率为92.2%。
- 意向性治疗分析显示,PCI组与OMT组相比,心绞痛频率评分变化为12.2 vs 8.6(P=0.009),生活质量变化为19.5 vs 11.3(P<0.001),SAQ汇总评分变化为13.8 vs 8.5(P<0.001)。
- 躯体活动受限差异仅达到Bonferroni多重检验校正水平(P=0.01)。
- SAQ评分变化个体间差异较大;生活质量显著改善的主要决定因素为低基线评分和接受PCI,性别、糖尿病或病变复杂性无影响。
- 平均随访3.1年,心脏死亡或非致死性心肌梗死两组相似(OMT vs PCI:2.7% vs 5.1%;P=0.17);卒中或出血住院率相似;仅靶病变血运重建OMT更频繁(18.8% vs 10.6%;P=0.005)。
临床怎么用
- 对于仅有一处慢性完全闭塞且无其他显著冠脉病变的患者,PCI可作为改善生活质量和心绞痛的有效选择。
局限性
- 该研究为事后汇总分析,非预设主要分析。
- SAQ评分变化个体间差异较大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The benefit of percutaneous coronary intervention (PCI) for chronic total coronary occlusions (CTOs) to improve clinical symptoms and quality of life (QoL) as compared with optimal medical therapy (OMT) is still under debate because of the scarcity of available randomized trials (RCTs). OBJECTIVES: We evaluated the effect of PCI vs OMT in patients with a CTO and no concomitant coronary lesions in a post-hoc pooled analysis of 2 RCTs. METHODS: A total of 518 patients with a single CTO and no other significant coronary lesion were extracted from 2 RCTs, EUROCTO and DECISION-CTO, which had compared PCI vs OMT. Randomization to PCI or OMT was 1:1 in DECISION and 2:1 in EUROCTO. The clinical status was assessed by the Seattle Angina Questionnaire (SAQ) at baseline and after 12 months, and clinical events were monitored for 3 years. RESULTS: PCI was successful in 92.2%. On an intention-to-treat analysis, PCI appeared to be superior to OMT for the change of angina frequency scores between baseline and follow-up (12.2 vs 8.6; P = 0.009), QoL (19.5 vs 11.3; P < 0.001), and the SAQ summary score (13.8 vs 8.5; P < 0.001). For physical limitation, the difference was just at the level of the Bonferroni correction for multiple tests (P = 0.01). There was a wide variability of changes in SAQ scores. For QoL, the major determinant for a significant improvement was a low baseline score and the assignment to PCI, whereas gender, diabetes, or lesion complexity had no influence. During a mean follow-up of 3.1 years, the clinical endpoints of cardiac death or nonfatal myocardial infarction were similar in both groups (OMT vs PCI: 2.7% vs 5.1%; P = 0.17). The rates of stroke or hospitalization for bleeding were similar, and only target lesion revascularizations were more frequent with OMT (18.8% vs 10.6%; P = 0.005). CONCLUSIONS: In this post-hoc analysis from 2 RCTs of patients with a single CTO and no significant concomitant lesion, PCI achieved better improvement in QoL, angina frequency, and the SAQ summary score than OMT with no signal of excess harm regarding clinical endpoints. (EUROCTO [Evaluate the Utilization of Revascularization or Optimal Medical Therapy for the Treatment of Chronic Total Coronary Occlusions; NCT01760083] and DECISION-CTO [Drug-Eluting Stent Implantation Versus Optimal Medical Treatment in Patients With Chronic Total Occlusion; NCT01078051]).
引用
- Werner GS, Kim JH, Hildick-Smith D, et al. Quality of Life After Percutaneous Coronary Intervention or Medical Therapy for Chronic Total Coronary Occlusions: EUROCTO and DECISION-CTO Meta-Analysis. J Am Coll Cardiol. 2026. PMID: 41949523. doi:10.1016/j.jacc.2026.02.5099
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。